Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Bearish
2
Neutral
6
Bullish
6
Bearish
28
Neutral
6
Bullish
12
Bearish
26
Neutral
0
Bullish
6
Discovery themes featuring this stock
Kabra Drugs Ltd, established in 1989, specializes in manufacturing ether derivatives along with other pharmaceutical and permaculture products.
The company has expanded its product line to include hand sanitizers and antimicrobial gels, becoming a sole manufacturer of some disinfectant products in India.
Kabra Drugs maintains state-of-the-art facilities approved by WHO-GMP, cGMP, and Schedule 'M', enabling business with government entities and NGOS.
Despite manufacturing capabilities, the company is facing operational challenges due to lack of working capital, prompting cost reduction efforts.
Kabra Drugs is a registered supplier to the Ministry of Defence and aims to expand its reach to global markets with new product developments.
Pharmaceuticals & Biotechnology
Pharmaceuticals
64 Cr
Moderate Risk
15.4
32.2
—
2.5
35.52
10.56
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
211.05 | 68 Cr | -38.94 | 0.97 | 0.45 | 2.22 | 4.92 | -1.28 | ||
79.30 | 68 Cr | 12.92 | 1.75 | 0.00 | 0.00 | 0.00 | 4.00 | ||
63.00 | 65 Cr | 22.66 | 1.26 | 0.00 | 2.54 | 6.69 | 1.80 | ||
28.40 | 64 Cr | 15.35 | 2.45 | 0.00 | 4.59 | 5.90 | 7.89 | ||
8.90 | 60 Cr | 6.14 | 0.80 | 0.00 | 8.41 | 12.26 | 4.11 | ||
7.50 | 60 Cr | -1.99 | 0.00 | 0.00 | 50.81 | -2.49 | -3.78 | ||
33.00 | 58 Cr | 9.97 | 1.05 | 0.00 | 1.95 | 4.14 | 1.16 | ||
| Median: 7 Co. | — | 33.00 | 64 Cr | 9.97 | 1.05 | 0.00 | 2.54 | 4.92 | 1.80 |
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
Kabra Drugs Ltd (KABRADG) is currently trading at 26.82 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Kabra Drugs Ltd, established in 1989, specializes in manufacturing ether derivatives along with other pharmaceutical and permaculture products. The company has expanded its product line to include hand sanitizers and antimicrobial gels, becoming a sole manufacturer of some disinfectant products in India. Kabra Drugs maintains state-of-the-art facilities approved by WHO-GMP, cGMP, and Schedule 'M', enabling business with government entities and NGOS. Despite manufacturing capabilities, the company is facing operational challenges due to lack of working capital, prompting cost reduction efforts. Kabra Drugs is a registered supplier to the Ministry of Defence and aims to expand its reach to global markets with new product developments.
Over the past 52 weeks, Kabra Drugs Ltd has traded between a low of ₹10.56 and a high of ₹35.52. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Kabra Drugs Ltd has a market capitalization of approximately 63.61. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Kabra Drugs Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 15.35 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 63.61 Cr, Kabra Drugs Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Kabra Drugs Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Kabra Drugs Ltd is 15.35. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Board Meeting Outcome
Board appointed Ms. Monam Kapoor as Additional Independent Director (21 Apr 2026–20 Apr 2031), approved amendment to the MOA to add new business lines (drones/defence, AI, medical, hospitality, dairy, agro) and approved a postal ballot (book closure 09 May–08 Jun 2026; e‑voting 09 May–08 Jun 2026).
Board Meeting Outcome
On 21 Apr 2026 Kabra Drugs' board appointed Ms. Monam Kapoor as Additional Independent Director (5-year term), approved proposed amendment to MOA to diversify into drones, AI, healthcare, hospitality, dairy & agro (subject to shareholder approval), approved postal ballot (including name change & object amendment), set book‑closure and e‑voting schedule, and appointed scrutinizer and compliance CA.
